Tc Biopharm Holdings Stock Today
| TCBP Stock | USD 2.44 0.02 0.81% |
PerformanceVery Weak
| Odds Of DistressVery High
|
TC BioPharm is selling at 2.44 as of the 18th of February 2025; that is 0.81 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.03. TC BioPharm has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of October 2024 and ending today, the 18th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of February 2022 | Category Healthcare | Classification Health Care |
TC Biopharm Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Tc Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 572.02 K outstanding shares of which 76.78 K shares are at this time shorted by private and institutional investors with about 0.05 trading days to cover. More on TC BioPharm Holdings
Moving together with TCBP Stock
Moving against TCBP Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
TCBP Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTC BioPharm can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TC BioPharm's financial leverage. It provides some insight into what part of TC BioPharm's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TC BioPharm Holdings (TCBP) is traded on NASDAQ Exchange in USA. It is located in Maxim 1, Motherwell, United Kingdom, ML1 4WR and employs 41 people. TC BioPharm is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 360.37 K. TC BioPharm Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 572.02 K outstanding shares of which 76.78 K shares are at this time shorted by private and institutional investors with about 0.05 trading days to cover.
TC BioPharm Holdings currently holds about 1.57 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Check TC BioPharm Probability Of Bankruptcy
Ownership AllocationAlmost 98.24 % of TC BioPharm outstanding shares are held by general public with 1.76 (percent) by institutions.
Check TCBP Ownership Details
TCBP Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Gamma Investing Llc | 2024-12-31 | 1.2 K | |
| Platform Technology Partners | 2024-09-30 | 0.0 | |
| Rhumbline Advisers | 2024-12-31 | 1.1 K | |
| Harbour Investments, Inc. | 2024-12-31 | 236 | |
| New England Capital Financial Advisors Llc | 2024-12-31 | 201 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 90.0 | |
| Toth Financial Advisory Corp | 2024-12-31 | 30.0 | |
| Sanctuary Wealth Management, Llc | 2024-09-30 | 12.0 | |
| Wells Fargo & Co | 2024-09-30 | 5.0 | |
| Signaturefd, Llc | 2024-12-31 | 0.0 | |
| Csenge Advisory Group, Llc | 2024-09-30 | 0.0 |
TC BioPharm Historical Income Statement
TCBP Stock Against Markets
TC BioPharm Corporate Management
| Michael MBA | CoFounder Chairman | Profile | |
| Lauren Bor | Head Division | Profile | |
| Martin Thorp | CFO Director | Profile | |
| Christopher Camarra | Executive Communications | Profile | |
| Bryan Kobel | CEO Director | Profile | |
| Angela Scott | CoFounder COO | Profile |
Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.